Relevant Disclosure with respect to Outcome of Board Meeting held on may 15, 2025 along with Financials Results and Audit Report is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Malar Hospitals reported audited FY25 results showing zero revenue from operations, as the company sold its hospital business to MGM Healthcare via a slump sale effective February 2024. Standalone Profit After Tax for FY25 was Rs. 5,603.54 lakhs (vs Rs. 4,727.68 lakhs in FY24), boosted by a large one-time dividend received; basic EPS came in at Rs. 29.90 vs Rs. 25.23. The Board approved the appointment of M/s Jitender, Navneet & Co. as Cost Auditor for FY26 and M/s Mukesh Agarwal & Co as Secretarial Auditor for five years (FY25-30). BSR & Co. LLP issued an unmodified opinion but flagged an Emphasis of Matter stating the company has ceased all business operations and management is evaluating corporate restructuring options, while still preparing accounts on a going-concern basis. Cash and bank balances stand at about Rs. 1,770 lakhs, which the company says is enough to meet ongoing obligations.
For shareholders, this is effectively a shell company now — there are no operating revenues and no plan for new business yet, though a large Rs. 7,965 lakh dividend was paid during FY25, indicating a possible return-of-capital path. The stock narrative may hinge on the outcome of the restructuring evaluation; until then, expect thin fundamentals, dependence on interest income, and overhang from a Rs. 22,535 lakh GST show-cause notice (assessed as remote by management).